Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | Q9HBH1 | 3/20 | 0.39 | |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13333385 | 1.00 | KMT2A (0.43) | KMT2APDFL3MBTL1MAPTLMNA | |
| SCHEMBL3323158 | 1.00 | KMT2A (0.43) | KMT2APDFL3MBTL1MAPTLMNA | |
| SCHEMBL13361595 | 1.00 | KMT2A (0.43) | KMT2APDFL3MBTL1MAPTLMNA | |
| SCHEMBL3317636 | 0.92 | SRD5A1 (0.46) | KMT2APDFL3MBTL1MAPTLMNA | |
| SCHEMBL3322046 | 0.92 | KMT2A (0.41) | KMT2APDFL3MBTL1MAPTLMNA | |
| SCHEMBL3322041 | 0.92 | KMT2A (0.41) | KMT2APDFL3MBTL1MAPTLMNA | |
| SCHEMBL3317642 | 0.92 | SRD5A1 (0.46) | KMT2APDFL3MBTL1MAPTLMNA | |
| SCHEMBL13361606 | 0.92 | KMT2A (0.41) | KMT2APDFL3MBTL1MAPTLMNA | |
| SCHEMBL14573454 | 0.92 | MMP1 (0.41) | KMT2AL3MBTL1MAPTLMNASRD5A1 | |
| SCHEMBL13333388 | 0.92 | MMP1 (0.41) | KMT2AL3MBTL1MAPTLMNASRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | KMT2A 3725/4885PDF 273/4885L3MBTL1 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.